Grifols announced that Flebogamma 10% DIF (dual inactivated, nano-filtered) intravenous immune globulin (IVIG) has been made available. Flebogamma DIF is already available in a 5% concentration. Flebogamma DIF is indicated for the treatment of primary immune deficiency (eg, common variable immunodeficiency, x-linked agammaglobulinemia, severe combined immunodeficiency, Wiskott-Aldrich syndrome).

For more information call (888) GRIFOLS or visit www.grifols.com.